IL1B and COVID-19: If LRG1 is angiopathic in COVID-19 patients, then inhibition of IL-6 may not be sufficient to stop LRG1 as IL-1β and TNFα, both prevalent in COVID-19 infected lungs50, are also capable of LRG1 induction4.